DTC Stock Chart & Stats
€0.23
>-€0.01(-0.87%)
At close: 4:00 PM EDT
€0.23
>-€0.01(-0.87%)
Day’s Range― - ―
52-Week Range€0.19 - €0.59
Previous CloseN/A
Volume5.00K
Average Volume (3M)7.08K
Market Cap
€18.73M
Enterprise Value€31.08
Total Cash (Recent Filing)€2.95M
Total Debt (Recent Filing)€1.56M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding75,788,155
10 Day Avg. Volume10,650
30 Day Avg. Volume7,084
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery Platform (Accum)A proprietary intracellular delivery platform is a structural asset: Accum® targets a core technical barrier for biologics and can be applied across oncology and infectious-disease programs. If validated, it supports durable program expansion, partner deals, and differentiated R&D productivity.
Positive Shareholders' Equity In Latest TTMA return to positive equity and rising total assets provide a fundamental buffer versus prior years of negative equity. This improves solvency metrics, extends runway versus insolvency, and gives management more flexibility in structuring future financing or partnerships.
Year-over-year Improvement In Net Loss (2024 To 2025)Material narrowing of losses year-over-year signals that cost control or program execution reduced spend intensity. Such improvement, if sustained, lowers future financing needs, demonstrates management discipline, and increases the chance of funding key milestones without immediate dilution.
Bears Say
No Revenue And Recurring LossesPersistent absence of revenue means the company remains fully development-stage and dependent on capital markets. Recurring multi‑million losses erode cash reserves, increase probability of dilution, and make long-term operational plans contingent on successful future financing or partnerships.
Negative Operating And Free Cash Flow (cash Burn)Sustained negative operating and free cash flow, alongside deteriorating FCF growth, indicate ongoing burn that will necessitate capital raises. That constrains strategic optionality, pressures R&D pacing, and raises execution risk if markets or partner interest weaken over a multi‑month horizon.
Prior Negative Equity And Outstanding DebtA history of negative equity and existing debt creates structural financing risk: leverage is harder to assess when equity swings negative, lenders may demand tighter terms, and investors face higher dilution likelihood if losses persist and further capital is required.
Defence Therapeutics News
DTC FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was €0.19 and its highest was €0.59 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is €18.73M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is Oct 28, 2026 which is in 86 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on May 22, 2026. The company reported -€0.031 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 75,788,155 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -€0.031 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.481%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in DE:DTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Technical Analysis
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―